The HESI Cardiac Safety Myocyte Subteam completed a validation study with the CiPA 28, two commercial human cardiomyocyte cell lines, 5 devices across 10 sites. The results are published here.
International Multisite Study of Human Induced Pluripotent Stem Cell Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment
Cell Reports, 2018